| Hormone refractory prostate cancer
Talzenna vs Xofigo
Side-by-side clinical, coverage, and cost comparison for hormone refractory prostate cancer.Deep comparison between: Talzenna vs Xofigo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXofigo has a higher rate of injection site reactions vs Talzenna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xofigo but not Talzenna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Talzenna
Xofigo
At A Glance
Oral
Daily
PARP inhibitor
IV injection
Every 4 weeks
Alpha particle-emitting radiopharmaceutical
Indications
- Malignant neoplasm of breast
- Hormone refractory prostate cancer
- Hormone refractory prostate cancer
Dosing
Malignant neoplasm of breast 1 mg orally once daily until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer 0.5 mg orally once daily with enzalutamide until disease progression or unacceptable toxicity; patients should also receive a GnRH analog concurrently or have had bilateral orchiectomy.
Hormone refractory prostate cancer 55 kBq (1.49 microcurie) per kg body weight by slow IV injection over 1 minute, every 4 weeks for 6 injections.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Fatigue, nausea, vomiting, diarrhea, headache, alopecia, decreased appetite, hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased
Serious Anemia, pyrexia
Most common (>=10%) Nausea, diarrhea, vomiting, peripheral edema; hematologic: anemia, lymphocytopenia, leukopenia, thrombocytopenia, neutropenia.
Serious Bone marrow suppression.
Pharmacology
Talazoparib is an inhibitor of PARP enzymes (PARP1 and PARP2) involved in DNA repair; it induces cytotoxicity in cancer cells with DNA repair gene defects through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage, decreased cell proliferation, and apoptosis.
Radium-223 mimics calcium and forms complexes with bone mineral hydroxyapatite at areas of increased bone turnover such as bone metastases; the high linear energy transfer of alpha particles leads to a high frequency of double-strand DNA breaks in adjacent tumor cells, resulting in an anti-tumor effect on bone metastases.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Talzenna
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Xofigo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Talzenna
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Xofigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Talzenna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Xofigo
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Talzenna.
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TalzennaView full Talzenna profile
XofigoView full Xofigo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.